SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-23-045249
Filing Date
2023-09-26
Accepted
2023-09-26 16:30:20
Documents
12
Period of Report
2023-08-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20011289_8ka.htm   iXBRL 8-K/A 24639
  Complete submission text file 0001140361-23-045249.txt   160876

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA erna-20230828.xsd EX-101.SCH 3865
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20230828_lab.xml EX-101.LAB 22546
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20230828_pre.xml EX-101.PRE 16044
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20011289_8ka_htm.xml XML 4235
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-11460 | Film No.: 231280808
SIC: 2834 Pharmaceutical Preparations